Quick Answer
ProQR Therapeutics N.V. reported Total Assets of $112.76 million for fiscal year 2025.
ProQR Therapeutics N.V. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Assets | $112.76M -32.9% |
$167.96M +21.8% |
$137.88M -19.5% |
$171.32M -18.3% |
$209.58M +112.3% |
$98.73M -16.0% |
| R&D Expense | $44.73M +23.0% |
$36.36M +44.6% |
$25.15M -50.6% |
$50.87M +20.5% |
$42.22M +10.7% |
$38.13M -18.0% |
- ProQR Therapeutics N.V. reported Total Assets of $112.76 million for fiscal year 2025.
- ProQR Therapeutics N.V. showed a decrease of -32.9% in Total Assets compared to the prior fiscal year.
- ProQR Therapeutics N.V. reported R&D Expense of $44.73 million for fiscal year 2025.
- ProQR Therapeutics N.V. showed an increase of +23.0% in R&D Expense compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: